Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Hemophilia Treatment Market – A Significant Management for Hemophilic Patients
Hemophilia, a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor, factor VIII. There are around 13 types of clotting factors that work with blood platelets to help the clotting. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in factor VIII. Hemophilia B occurs due to deficiency of factor IX and Hemophilia C is caused due to factor XI deficiency.
Novel product launches by market players in the hemophilia treatment are expected to boost growth of the market over the forecast period. For instance, in June 2019, Novo Nordisk received marketing authorization from the European Commission for ‘Esperoct’ in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency). Moreover, in April 2019, Roche Products India Pvt. Ltd launched hemophilia A drug Emicizumab, branded as Hemlibra in India. It is indicated for prophylactic treatment for reducing frequency of bleeding episodes in patients with hemophilia A, through Factor VIII inhibitors.
Furthermore, increasing government initiatives to promote awareness about hemophilia treatment among the populace is expected to propel growth of the market over the forecast period. For instance, the National Bleeding Authority (NBA) provides funding to AHCDO (Australian Hemophilia Center Directors’ Organization) for treatment and management of hemophilia A (Factor VIII Deficiency) in Australia.
The global hemophilia treatment market size was valued at US$ 11,474.3 million in 2018, and is expected to exhibit a CAGR of 5.9% over the forecast period (2019-2027).
Figure 1. Global Hemophilia Treatment Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Rising cases of bleeding disorders is expected to boost growth of the global hemophilia treatment market
The global hemophilia treatment market is expected to witness significant growth owing to rising incidence of hemophilia or bleeding disorders. For instance, according to the Australian Bleeding Disorders Registry, in 2015, there were around 4,941 patients who suffered from common hereditary bleeding disorders, out of which 2,301 patients were diagnosed with hemophilia A, and 548 patients were diagnosed with hemophilia B in Australia. Thus, increasing prevalence of hemophilia is expected to drive demand for hemophilia treatment over the forecast period. Moreover, increasing demand for efficient therapeutics for treatment of factor VIII deficiency from emerging economies such as India is expected to drive the market growth over the forecast period. For instance, according to the World Federation of Hemophilia’s 2017 statistics, in India, around 18,353 people were diagnosed with hemophilia in 2016.
Figure 2. Global Hemophilia Treatment Market Share (%), by Product Type, 2019 and 2027
Source: Coherent Market Insights Analysis (2019)
Increasing healthcare expenditure and reimbursement policies in respective countries or regions are expected to drive the market growth
North America is projected to hold a dominant position in the global hemophilia treatment market owing to increasing strategic partnerships and collaborations, which is expected to drive growth of the North America market growth over the forecast period. For instance, in April 2014, Biogen, Inc. signed a license agreement with Amunix Operating Inc., a California-based biotechnology company, for research and development of novel, fully-recombinant Factor VIII products with improved therapeutic properties. Under the license agreement, Biogen is focused on development of XTENylated Factor VIII products for treatment of factor VIII deficiency.
Moreover, Asia Pacific is expected to witness the second largest growth in the global hemophilia treatment market owing to rising favorable reimbursement policies for hemophilia treatment in economies such as China. For instance, according to the report published by the Chinese Ministry of Health in 2012, outpatient hemophilia treatment is covered by health insurance schemes in over 80% of the cities in China. Moreover, annual reimbursement is usually accounted below US$ 16,000.
Major players operating in the global hemophilia treatment market include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, F. Hoffmann-La Roche AG.